EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual
Healthcare Conference
TARRYTOWN, N.Y., Oct. 30 -- EpiCept Corporation
(Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley,
President and CEO, will be presenting at the Acumen BioFin Rodman & Renshaw 9th
Annual Healthcare Conference on November 5, 2007 at 10:15 a.m. Eastern Time at
The New York Palace Hotel in New York. Mr. Talley will present a company
overview.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
The presentation will be available live via webcast on November 5, 2007 and for
90 days thereafter. The webcast can be accessed by visiting www.epicept.com or
http://www.wsw.com/webcast/rrshq12/epct.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept
has a staged portfolio of pharmaceutical product candidates with several pain
therapies in late-stage clinical trials, and a lead oncology compound (for acute
myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a
marketing authorization application for this compound has been submitted in
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development
team in San Diego is pursuing a drug discovery program focused on novel
approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that the proposed public offering will not be consummated,
the risks associated with our need to raise additional financing to continue to
meet our capital needs and our ability to continue as a going concern, the risk
that Ceplene will not receive regulatory approval or marketing authorization in
the EU or that Ceplene, if approved, will not achieve significant commercial
success, the risk that Myriad's development of Azixa(TM)* will not be
successful, the risk that Azixa will not receive regulatory approval or achieve
significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myriad, the risk that the
development of our other apoptosis product candidates will not be successful,
the risk that our ASAP technology will not yield any successful product
candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be
successful, that NP-1 or EPC 2407 will not receive regulatory approval or
achieve significant commercial success, the risk that our other product
candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later stage clinical
trials, the risk that EpiCept will not obtain approval to market any of its
product candidates, the risks associated with dependence upon key personnel, the
risks associated with reliance on collaborative partners and others for further
clinical trials, development, manufacturing and commercialization of our product
candidates; the cost, delays and uncertainties associated with our scientific
research, product development, clinical trials and regulatory approval process;
our history of operating losses since our inception; competition; litigation;
risks associated with prior material weaknesses in our internal controls; and
risks associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in EpiCept's periodic
reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings
with the U.S. Securities and Exchange Commission. You are urged to carefully
review and consider the disclosures found in EpiCept's filings which are
available at www.sec.gov or at www.epicept.com. You are cautioned not to place
undue reliance on any forward-looking statements, any of which could turn out to
be wrong due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors.
EPCT-GEN
*Azixa is a registered trademark of Myriad Genetics, Inc.
SOURCE EpiCept Corporation
-0- 10/30/2007
/CONTACT: Robert W. Cook of EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; Media, Greg Kelley of Feinstein Kean Healthcare,
+1-617-577-8110, gregory.kelley@fkhealth.com; Investors, Kim Sutton Golodetz,
+1-212- 838-3777, kgolodetz@lhai.com or Bruce Voss, +1-310-691-7100,
bvoss@lhai.com, both of Lippert Heilshorn & Associates/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
/Web site: http://www.epicept.com
http://www.wsw.com/webcast/rrshq12/epct /
(EPCT)
EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
| Source: Immune Pharmaceuticals Inc
Attachments
